查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1195582

高级药物输送系统 (ADDS) 市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Advanced Drug Delivery Systems Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

高级药物输送系统 (ADDS) 市场预计在预测期内 (2022-2027) 的复合年增长率为 5.3%。

COVID-19 大流行对市场增长率产生了积极影响。 几项研究强调了 ADDS 如何帮助为现有疗法开发改进的递送系统（剂型）。 例如，2020 年 6 月，瑞典查尔姆斯理工大学、哥德堡大学和阿斯利康启动了一项新的关键研究，研究针对 COVID-19 的鼻腔喷雾 mRNA 疫苗，结合了许多有前途的概念。 该团队研究了含有免疫增强剂和靶蛋白的仿生纳米粒子，以探索鼻腔免疫的设计原理。 Chalmers Innovation Office、Chalmers Advanced Health Engineering Area、瑞典战略研究基金会和瑞典研究委员会为这项工作做出了贡献。

此外，2020 年 4 月，Bioavanta-Bosti 利用其 Novochizol 壳聚醣多醣纳米技术，开发了一种适用于治疗 COVID-19 患者的局部和缓释肺内给药製剂的 API。或开发了一个 48 小时的製造工艺来封装生物製剂。 2020 年，Bioavanta-Bosti 还将与药物开发人员和临床研究人员合作，製造改变用途的药物或新型分子或生物製剂，以治疗肺部严重的 COVID-19 感染。我报告说我正在寻求合作关係。 ADDS 支持搜索新知识以识别未来目标分布的未探索领域，并在製药行业和学术机构中迅速传播。 因此，COVID-19 对市场增长产生了重大影响。

此外，推动该市场增长的因素包括新药和生物製剂的开发、对人类生物学和疾病的了解不断加深，以及研发成本不断增加。

生物学相关工作的多项进展正在创造独特的机会，以更好地了解人类疾病的分子后果，并根据这些因素开发新药和生物製品。. 最近发现的先进药物递送系统包括脂质、蛋白质和聚合物技术，可以提供良好的体内脂质分布，防止药物被外部环境降解，降低药物清除率。 先进的药物和生物製剂以较低的剂量更有效。 因此，它们必须得到先进的药物输送系统的支持才能发挥最大功效。

除了药物和生物製剂，药物洗脱植入物还有可能实现不间断治疗和减少药物剂量（从而降低给药频率）。 先进的缓释系统有助于治疗肠道感染等疾病。 随着自动注射器的发展趋势以及生物製剂/生物仿製药和自动注射器管道的迅速扩张，它们最近已成为一类重要的医疗器械。 许多公司都专注于推出有助于市场增长的新产品。 例如，2020 年 12 月，Agile Therapeutics, Inc. 在美国将 Twirla（左炔诺孕酮和乙炔雌二醇）透皮系统商业化，这是一种新的非常规、非侵入性避孕贴剂。 此外，2022 年 2 月，NewGen Medical Devices, Inc. 向台湾医疗分销商信亚生物科技发出了 Insjet 无针注射器的采购订单。 这是一项多年期销售和分销协议的一部分，前两年至少需要 100,000 加元，其余三年的未来承诺将按顺序确认。 此类合同也有助于市场的增长。

同样，duocap（胶囊中胶囊）、电胶囊、发光给药监测技术（LDMT）等为配製难溶性化合物和监测药物释放动力学提供了新方法。靶向口服给药的示例系统。 正在开发先进的药物递送系统以解决溶解度问题并使药物更具亲脂性。 这使得它很容易穿过体内的脂质屏障，最终防止光降解和pH变化等外部问题影响药物，进而在所需位置输送所需浓度，从而达到最大的治疗效果。 . 因此，这些新兴市场的发展有望对市场增长产生积极影响。

但是，先进给药产品的产品召回以及使用纳米药物给药的挑战可能会阻碍市场增长。

先进药物输送系统的市场趋势

按类型分，口服给药系统细分市场在预测期内将保持高速增长

口服给药是医生和患者最常用和首选的给药途径。 对这种给药途径的大部分需求是由于摄入的便利性和广泛的治疗适应症的可用性，从而导致潜在的毒性和副作用较低。

随着新药开发、专利申请和营销的成本和復杂性的增加，製药公司同时认识到控製药物递送的治疗益处，并对开发和改进口服释放药物递送系统表现出极大的兴趣。我正在发送。 在过去十年中，口服释放给药系统因其灵活性、降低给药频率和提高患者依从性而受到广泛关注。 上述因素，加上口服控释给药系统的合理成本，导致了这种给药途径的流行。

在中枢神经系统、心血管、代谢和呼吸系统疾病等关键治疗领域的市场扩张和新推出的控释製剂的推动下，先进口服给药系统的开发正在加速这是因为 例如，2020 年，Progenity 公布了其口服给药系统（DDS）DDS Capsules 的性能，该系统采用专有的自主立体定向技术，旨在定位胃肠道的迴肠/迴盲部区域。报告了良好的初步临床前数据 该技术基于解剖学，旨在承受生理条件的变化，例如 pH 值、运动性和细菌。 此类产品的推出将为该行业在不久的将来提供增长机会。

口服薄膜药物等先进的药物输送系统因其高临床疗效和抗病功效而受到越来越多的需求。 例如，2021年6月，Silpa Medicare Co., Ltd.推出商品名为“Morcil”的儿科扑热息痛口服薄膜製剂。 Silpa在完全满足生物等效性要求后，获得了Morcil口服薄膜製剂的批准。 我们的扑热息痛口服薄膜配方受专利保护，是世界上同类产品中的首创。

因此，由于上述因素，预计口服给药领域在预测期内将会增长。

北美主导市场，预计在预测期内将继续保持同样的趋势

北美目前主导着全球先进药物输送系统市场。 这是由于越来越多地采用改进的药物输送解决方案以及医疗保健中先进治疗方法的跟进。 美国是该地区最大的市场。 对药物自我管理的日益偏好、可注射药物输送系统的创新不断增加、新医疗技术的广泛采用以及慢性病的高患病率是美国先进药物输送系统市场的主要驱动力。它是

心脏病是导致该国人民、社区、医疗保健提供者和系统负担的主要原因。 在美国，大约一半的成年人患有某种形式的心血管疾病。 据美国癌症协会预测，2022 年美国将诊断出近 200 万新癌症病例，约 60.9 万人将死于癌症。 如此高的疾病负担创造了对先进药物输送系统的有效治疗需求，并促进了市场的增长。

此外，市场参与者、非营利组织和政府机构的联合举措也在推动该地区的市场增长。 例如，2022 年 3 月，TFF Pharmaceuticals 将成为美国陆军医学研究与发展司令部和美国陆军传染病研究部的一部分，后者是美国陆军针对生物武器进行防御性研究的首要机构和设施 (USAMRIID) 以及日内瓦基金会，一个促进美国军方创新医学研究的非营利组织。 根据协议条款，TFF Pharmaceuticals 和 USAMRIID 将开发使用 TFF 的薄膜冷冻技术配製的干粉重组水泡性口炎病毒严重急性呼吸系统综合症冠状病毒 2 型糖蛋白（TFFD-RVSV-SARS2。-GP）将评估疫苗的免疫反应。 预计此类联合举措将推动市场增长。

因此，由于上述因素，预计北美地区在预测期内将出现增长。

先进药物输送系统市场的竞争对手分析

先进给药系统市场的竞争很低。 药物输送系统的持续技术进步可能会在未来几年引入新的进入者。 该市场的主要参与者包括波士顿科学公司、百特国际、Becton Dickinson & Company、Kindeva Drug Delivery L.P.

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 新药和生物製品的开发
    • 在理解人类生物学和疾病方面取得的进展
    • 研发费用增加
  • 市场製约因素
    • 召回先进的给药产品
    • 使用纳米药物输送药物的挑战
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按类型
    • 口服给药系统
    • 注射给药系统
    • 用于吸入/呼吸系统的给药系统
    • 透皮给药系统
    • 跨粘膜给药系统
    • 基于载体的给药系统
    • 其他类型
  • 通过申请
    • 心血管疾病
    • 肿瘤学
    • 泌尿科
    • 糖尿病
    • 中枢神经系统
    • 眼科
    • 感染
    • 其他应用
  • 按技术
    • 前药
    • 植入物和宫内节育器
    • 靶向给药
    • 聚合物药物输送
    • 其他技术
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Becton, Dickinson and Company
    • Abbott Laboratories
    • Baxter
    • Bayer AG
    • Boston Scientific Corporation
    • Kindeva Drug Delivery L.P.
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • Medtronic
    • Ypsomed
    • Abbvie, Inc.
    • Astrazeneca

第7章 市场机会与今后动向

简介目录
Product Code: 53008

The advanced drug delivery systems (ADDS) market is expected to register a CAGR of 5.3% during the forecast period (2022-2027).

The COVID-19 pandemic had positively impacted the market's growth rate. Several studies emphasize how ADDS will help develop improved delivery systems (dosage forms) of existing therapeutic agents. For instance, in June 2020, the Chalmers University of Technology in Sweden, the University of Gothenburg, and AstraZeneca started new pivotal research combining many promising concepts to investigate a nasal spray mRNA vaccine against COVID-19. The team was working on a biomimetic nanoparticle that contains both immune enhancers and a targeting protein to investigate design principles for nasal immunization. The Chalmers Innovation Office, the Chalmers Area of Advance Health Engineering, the Swedish Foundation for Strategic Research, and the Swedish Research Council contributed to the initiative.

Additionally, in April 2020, Bioavanta-Bosti developed a 48-hour manufacturing process using its Novochizol chitosan polysaccharide nanotechnology to encapsulate APIs or biologics for localized delivery and sustained release intra-pulmonary drug delivery formulations, which are suitable for treating COVID-19 patients. Bioavanta-Bosti also reported in 2020 that it is looking for collaborations with drug developers and clinical researchers to produce a repurposed medicine or new molecular or biological entity formulations to treat severe COVID-19 infection in the lungs. ADDS has aided in exploring new insights to identify untapped areas for future targeted distribution, and it is quickly gaining traction in the pharmaceutical sector and academic institutions. Thus, COVID-19 has had a significant impact on the growth of the market.

Furthermore, the factors driving this market's growth include the development of new drugs and biologics; advancements in understanding human biology and diseases; and increased R&D spending.

Advancements in several biology-oriented initiatives have created a unique opportunity to better understand the molecular effects of human diseases and develop novel drugs and biologics based on these factors. The recently discovered advanced drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, preventing drug degradation due to the external environment and reducing the rate of drug clearance. Advanced drugs and biologics have higher efficiency with a smaller dosage of drugs. Hence, they must be supported with advanced drug delivery systems to gain maximum efficacy.

In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and a reduction in drug dosage (hence a less frequent need for dosing). The advanced sustained release systems help target intestinal infections and others. The trend toward self-injection devices and the rapidly growing pipeline of biologics/biosimilars and auto-injectors have also recently emerged as an important class of medical devices. Many companies are focusing on the launch of new products that will contribute to market growth. For instance, in December 2020, Agile Therapeutics, Inc., commercially launched Twirla (levonorgestrel and Ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch in the United States. Additionally, in February 2022, Nu Gen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor, Shin-Ya Biotechnology Co., Ltd., for its InsuJet needleless injection system. This is part of a multi-year sales and distribution agreement with a minimum commitment of CDN 100,000 over the first two years, with future commitments for the remaining three years of the agreement to be finalized in due course. Such agreements are also contributing to the growth of the market.

Likewise, Duocap (capsule-in-a-capsule), electrocapsule, and light-up delivery monitoring technology (LDMT) are some of the controlled and targeted oral drug delivery systems that provide a new way of formulating poorly soluble compounds and monitoring the release rate of drugs. Advanced drug delivery systems are being developed to resolve solubility problems and make the drugs more lipid-soluble. Thus, this enables them to easily cross lipid barriers in the body, eventually preventing external issues, such as photodegradation and pH changes, from affecting the drug and further achieving the desired concentration at the desired location to provide the maximum therapeutic effect. Thus, these developments are expected to positively impact the market's growth.

However, product recalls of advanced drug delivery products and challenges in nanomedicine-based drug delivery may hinder the growth of the market.

Advanced Drug Delivery Systems Market Trends

The Oral Drug Delivery System Segment by Type to Hold the High Growth Over the Forecast Period

The oral drug delivery method is the most common and preferred drug administration route by the physician and the patient. The demand for this route of administration mostly lies in the convenience of intake and the availability of a broad window of the therapeutic index, which, in turn, lowers the possibility of toxicity and side effects.

With increasing costs and complications in developing, patenting, and marketing new drug entities, pharmaceutical companies, with simultaneous recognition of the therapeutic advantages of controlled drug delivery, are paying greater attention to developing and modifying oral-release drug delivery systems. Over the last decade, oral release drug delivery systems have received extensive attention owing to their flexibility, reduced dosing frequency, and better patient compliance. The aforesaid factors, in combination with the reasonable cost of oral controlled release drug delivery systems, led to greater adoption of this route of administration.

The accelerated pace of advanced oral drug delivery system development is fostered by a growing market of controlled release formulations and new launches in key therapeutic areas such as the central nervous system and cardiovascular, metabolic, and respiratory diseases. For instance, in 2020, Progenity Inc. reported positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS), the DDS capsule, which uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the GI tract. This technology is based on anatomy and is designed to resist variability in physiological conditions like pH, motility, and bacteria. The launch of such products will provide growth opportunities for the segment in the near future.

The demand for advanced drug delivery systems such as oral thin-film drugs is rising due to their high clinical efficacy and effectiveness against diseases. For instance, in June 2021, Shilpa Medicare Ltd. launched an oral thin film formulation, a pediatric dose of paracetamol oral thin film, under the brand name Molshil. Shilpa received approval for Molshil oral thin films after sufficiently complying with bioequivalence requirements. Shilpa's Paracetamol oral thin films are patent protected and are the first of their kind in the world.

Thus, owing to the abovementioned factors, the oral drug delivery segment is expected to grow during the forecast period.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America currently dominates the global advanced drug delivery systems market owing to the better adoption of improved drug delivery solutions and follow-up of advanced treatment approaches in healthcare. The United States is the largest market in the region. The growing inclination toward self-administration of drugs, increasing innovations in injectable drug delivery systems, the high adoption rate of new healthcare technologies, and the high prevalence of chronic diseases are the primary drivers for the United States advanced drug delivery systems market.

Heart disease is a leading cause of death that burdens people, communities, healthcare providers, and systems in the country. Nearly half of all adults in the United States have some form of cardiovascular disease. According to the American Cancer Society, nearly 2 million new cancer cases are expected to be diagnosed, and around 609,000 people will die from cancer in the United States in 2022. Such a high burden of diseases creates demand for advanced drug delivery systems for effective treatment and thus drives the growth of the market.

Additionally, the joint initiatives taken by the market players, non-profit organizations, and government agencies are also propelling the growth of the market in the region. For instance, in March 2022, TFF Pharmaceuticals, Inc. entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), part of the United States Army Medical Research and Development Command and the United States Army's premier institution and facility for defensive research into countermeasures against biological warfare, and the Geneva Foundation, a non-profit that advances innovative medical research within the United States military. As per the agreement, TFF Pharmaceuticals and USAMRIID will evaluate the immune response of a dry powder recombinant Vesicular Stomatitis Virus Severe Acute Respiratory Syndrome Coronavirus-2 Glycoprotein (TFFD-rVSV-SARS2-GP) vaccine formulated using TFF's Thin Film Freezing technology. Such joint initiatives are also expected to propel the growth of the market.

Thus, owing to the abovementioned factors, the North American region is expected to show growth over the forecast period.

Advanced Drug Delivery Systems Market Competitor Analysis

The advanced drug delivery systems market is moderately competitive. Owing to the continuous technological advancements in the drug delivery system, there are possibilities for newer players to enter the market over the coming years. Some major players in this market are Boston Scientific Corporation, Baxter International, Becton, Dickinson and Company, Kindeva Drug Delivery L.P., and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Development of New Drugs and Biologics
    • 4.2.2 Advancements in Understanding Human Biology and Diseases
    • 4.2.3 Increased R&D Spending
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls of Advanced Drug Delivery Products
    • 4.3.2 Challenges in Nanomedicine-based Drug Delivery
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Oral Drug Delivery System
    • 5.1.2 Injection-based Drug Delivery System
    • 5.1.3 Inhalation/Pulmonary Drug Delivery System
    • 5.1.4 Transdermal Drug Delivery System
    • 5.1.5 Trans mucosal Drug Delivery System
    • 5.1.6 Carrier-based Drug Delivery System
    • 5.1.7 Other Types
  • 5.2 By Application
    • 5.2.1 Cardiovascular Diseases
    • 5.2.2 Oncology
    • 5.2.3 Urology
    • 5.2.4 Diabetes
    • 5.2.5 Central Nervous System
    • 5.2.6 Ophthalmology
    • 5.2.7 Infections
    • 5.2.8 Other Applications
  • 5.3 By Technology
    • 5.3.1 Prodrug
    • 5.3.2 Implants and Intrauterine Devices
    • 5.3.3 Targeted Drug Delivery
    • 5.3.4 Polymeric Drug Delivery
    • 5.3.5 Other Technologies
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Baxter
    • 6.1.4 Bayer AG
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Kindeva Drug Delivery L.P.
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 Medtronic
    • 6.1.11 Ypsomed
    • 6.1.12 Abbvie, Inc.
    • 6.1.13 Astrazeneca

7 MARKET OPPORTUNITIES AND FUTURE TRENDS